Dr Marco Corsi was trained as a physician with a specialization in Tropical Medicine from the University of Rome. He has served as Director of Clinical Research (R&D) at Sigma Tau for 35 years, developing drugs in cardiovascular diseases, oncology, and tropical diseases, and coordinating the clinical development of Eurartesim (DHA/PQP) which has been approved by the European Medicine Agency in 2011 and later in the endemic countries. He works as a consultant for the development of drugs in malaria.